Clinical prediction of benefits from preoperative maximum androgen blocking therapy in high-risk localized prostate cancer

Huang Yong; Zhou Fulin; Li Jing; Zhang Yao

doi:10.13406/j.cnki.cyxb.003795

您当前的位置：

首页 >

文章列表页 >

Clinical prediction of benefits from preoperative maximum androgen blocking therapy in high-risk localized prostate cancer

Neurogenic Lower Urinary Tract Dysfunction and Pelvic Floor Functional Restoration Column | 更新时间：2025-10-22

- Clinical prediction of benefits from preoperative maximum androgen blocking therapy in high-risk localized prostate cancer
- Journal of Chongqing Medical University Vol. 50, Issue 4, Pages: 463-469(2025)
- 作者机构：
  
  1.重庆医科大学附属第一医院泌尿外科，重庆 400016
  2.重庆医科大学第一临床学院，重庆 401331
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003795
  CLC： R697.03
- Received：23 January 2025，
  
  Revised：2025-02-07，
  
  Accepted：26 February 2025，
  
  Published：28 April 2025
- 稿件说明：
移动端阅览
黄勇,周福林,李静,等.高危局限性前列腺癌术前最大雄激素阻断治疗获益的临床预测[J].重庆医科大学学报,2025,50(4):463-469.

Huang Yong,Zhou Fulin,Li Jing,et al.Clinical prediction of benefits from preoperative maximum androgen blocking therapy in high-risk localized prostate cancer[J].Journal of Chongqing Medical University,2025,50(4):463-469.
黄勇,周福林,李静,等.高危局限性前列腺癌术前最大雄激素阻断治疗获益的临床预测[J].重庆医科大学学报,2025,50(4):463-469. DOI： 10.13406/j.cnki.cyxb.003795.

Huang Yong,Zhou Fulin,Li Jing,et al.Clinical prediction of benefits from preoperative maximum androgen blocking therapy in high-risk localized prostate cancer[J].Journal of Chongqing Medical University,2025,50(4):463-469. DOI： 10.13406/j.cnki.cyxb.003795.

摘要

目的

开发1种预测模型用于选择适合行最大雄激素阻断（maximum androgen blocking，MAB）治疗的高危局限性前列腺癌（high-risk localized prostate cancer，HRLPC）患者。

方法

本研究收集了2021年1月1日至2024年6月30日，在重庆医科大学附属第一医院泌尿外科经穿刺活检病理诊断并接受根治性前列腺切除术的96例HRLPC患者，所有患者在术前均接受3个月的MAB治疗，术后随访6个月。收集患者的基线人口学特征、实验室数据、影像学表现、围手术期临床资料及随访资料等。首先探究MAB治疗后前列腺特异性抗原密度（prostate-specific antigen density，PSAD）分层与病理和生化获益的关系，以确定最佳PSAD组别；随后采用机器学习筛选重要变量，构建预测模型，并通过ROC曲线、校准曲线及临床适用性评估其表现。

结果

低PSAD组［PSAD

0.17 ng/（mL∙cm

）］在围手术期结果、病理降级、术后检测不到前列腺特异抗原（prostate specific antigen，PSA）率、尿失禁恢复率及PSA随访情况均明显优于对照组（

0.05）。用于模型构建的变量包括前列腺体积、低密度脂蛋白胆固醇、PSAD、吸烟史、总胆固醇、P

SA、体质量指数，该预测模型的效能较好（AUC=0.769），具备一定的临床适用性。

结论

低PSAD组患者具有更好的病理和生化获益。本研究提供了1个可靠的预测模型，以辅助HRLPC患者的个体化治疗。

Abstract

Objective

To develop a predictive model for selecting patients with high-risk localized prostate cancer（HRLPC） who are suitable for preoperative maximum androgen blocking（MAB） therapy.

Methods

This study was conducted among 96 patients with HRLPC who were diagnosed based on transrectal biopsy and underwent radical prostatectomy in Department of Urology，The First Affiliated Hospital of Chongqing Medical University，from January 1，2021 to June 30，2024，and all patients received MAB therapy for 3 months before surgery and were followed up for 6 months after surgery. Related data were collected from all patients，including baseline demographic features，laboratory data，imaging findings，perioperative data，and follow-up information. At first，the association between prostate-specific antigen density（PSAD） stratification after MAB therapy and pathological and biochemical benefits was analyzed to determine the optimal PSAD group，then machine learning was used to identify important variables and establish a predictive model，and finally，the model was evaluated using the ROC curve，the calibration curve，and clinical applicability assessment.

Results

The low PSAD group ［PSAD

0.17 ng/（mL∙cm

）］ showed the best results of perioperative outcomes，pathological downgrading，the rate of undetectable PSA after -surgery，recovery from urinary incontinence，and PSA follow-up（

0.05）. The model was established based on prostate volume，low-density lipoprotein cholesterol，PSAD，smoking history，total cholesterol，PSA，and body mass index，and this predictive model had good performance （with an area under the ROC curve of 0.769） and showed a certain degree of clinical applicability.

Conclusion

Patients in the low PSAD group tend to have better pathological and biochemical benefits. This study provides a reliable predictive model to assist in the individualized treatment of patients with HRLPC.

关键词

Keywords

references

Diao X ， Guo C ， Jin Y ， et al . Cancer situation in China：an analysis based on the global epidemiological data released in 2024 [J ] . Cancer Commun （Lond）， 2025 ， 45 （ 2 ）： 178 - 197 ．

Zhang SW ， Sun KX ， Zheng RS ， et al . Cancer incidence and mortality in China，2015 [J ] . J Natl Cancer Cent ， 2021 ， 1 （ 1 ）： 2 - 11 ．

Han BF ， Zheng RS ， Zeng HM ， et al . Cancer incidence and mortality in China，2022 [J ] . J Natl Cancer Cent ， 2024 ， 4 （ 1 ）： 47 - 53 ．

Mottet N ， Bellmunt J ， Bolla M ， et al . EAU-ESTRO-SIOG guidelines on prostate cancer. part 1：screening，diagnosis，and local treatment with curative intent [J ] . Eur Urol ， 2017 ， 71 （ 4 ）： 618 - 629 ．

Chang AJ ， Autio KA ， Roach M ， et al . High-risk prostate cancer：classification and therapy [J ] . Nat Rev Clin Oncol ， 2014 ， 11 ： 308 - 323 ．

McKay RR ， Ye H ， Xie W ， et al . Evaluation of intense androgen deprivation before prostatectomy：a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone [J ] . J Clin Oncol ， 2019 ， 37 （ 11 ）： 923 - 931 ．

Devos G ， Tosco L ， Baldewijns M ， et al . ARNEO：a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer [J ] . Eur Urol ， 2023 ， 83 （ 6 ）： 508 - 518 ．

Shelley MD ， Kumar S ， Wilt T ， et al . A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma [J ] . Cancer Treat Rev ， 2009 ， 35 （ 1 ）： 9 - 17 ．

Kumar S ， Shelley M ， Harrison C ， et al . Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer [J ] . Cochrane Database Syst Rev ， 2006 （4）：CD006019．

Schwarzenböck SM ， Knieling A ， Souvatzoglou M ， et al . 11C] Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy [J ] . Oncotarget ， 2016 ， 7 （ 39 ）： 63747 - 63757 ．

Kafka M ， Burtscher T ， Fritz J ， et al . Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response [J ] . World J Urol ， 2023 ， 41 （ 8 ）： 2043 - 2050 ．

Nordström T ， Akre O ， Aly M ， et al . Prostate-specific antigen （PSA） density in the diagnostic algorithm of prostate cancer [J ] . Prostate Cancer Prostatic Dis ， 2018 ， 21 ： 57 - 63 ．

Washino S ， Okochi T ， Saito K ， et al . Combination of prostate imaging reporting and data system （PI-RADS） score and prostate-specific antigen （PSA） density predicts biopsy outcome in prostate biopsy naïve patients [J ] . BJU Int ， 2017 ， 119 （ 2 ）： 225 - 233 ．

Yikilmaz TN ， Ozturk E ， Hizli F ， et al . Effect of hormonal therapy for volume reduction，lower urinary tract symptom relief and voiding symptoms in prostate cancer：leuprolide vs goserelin [J ] . Urol J ， 2019 ， 16 （ 2 ）： 157 - 161 ．

Shim M ， Bang WJ ， Oh CY ， et al . Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer：Goserelin versus triptorelin versus leuprolide [J ] . Investig Clin Urol ， 2019 ， 60 （ 4 ）： 244 - 250 ．

Donohue JF ， Bianco FJ ， Kuroiwa K ， et al . Poorly differentiated prostate cancer treated with radical prostatectomy：long-term outcome and incidence of pathological downgrading [J ] . J Urol ， 2006 ， 176 （ 3 ）： 991 - 995 ．

Pylväläinen J ， Talala K ， Raitanen J ， et al . Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result [J ] . BJU Int ， 2025 ， 177 （ 1 ）： 751 - 780 .

Verit A . Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer：is it correlated with serum testosterone level? [J ] . BJU Int ， 2010 ， 106 （ 10 ）： 1555 ．

Narita S ， Mitsuzuka K ， Tsuchiya N ， et al . Reassessment of the risk factors for biochemical recurrence in D’Amico intermediate-risk prostate cancer treated using radical prostatectomy [J ] . Int J Urol ， 2015 ， 22 （ 11 ）： 1029 - 1035 ．

Deng CF ， Zhu N ， Zhao TJ ， et al . Involvement of LDL and ox-LDL in cancer development and its therapeutical potential [J ] . Front Oncol ， 2022 ， 12 ： 803473 ．

Zhao R ， Cheng G ， Wang B ， et al . BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people [J ] . Oncotarget ， 2017 ， 8 （ 39 ）： 66051 - 66060 ．

Calle EE ， Kaaks R . Overweight，obesity and cancer：epidemiological evidence and proposed mechanisms [J ] . Nat Rev Cancer ， 2004 ， 4 ： 579 - 591 ．

Massengill JC ， Sun L ， Moul JW ， et al . Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy [J ] . J Urol ， 2003 ， 169 （ 5 ）： 1670 - 1675 ．

Shiota M ， Ushijima M ， Imada K ， et al . Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy [J ] . Prostate ， 2019 ， 79 （ 10 ）： 1147 - 1155 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Prediction of postoperative hypotension risk in pheochromocytoma/paraganglioma patients: development and evaluation of a novel prediction nomogram

Development and internal validation of a prognostic model of metachronous dual primary lung cancer based on SEER database

Predictive value of a nomogram based on enhanced T1WI radiomics and clinico-MRIomics for aggressive histological types of endometrial cancer before surgery

MRI radiomics combined with clinical indices and LI-RADS features for predicting tumor response after transarterial chemoembolization in patients with intermediate and advanced hepatocellular carcinoma

Related Author

Peng Yueqiang

Zhang Gaojie

Wang Linfeng

Huang Yong

Xu Qiao

Yuan Ye

Du Jiajun

Shen Hongchang

Related Institution

Department of Urology， the 13th People's Hospital of Chongqing

Shandong Provincial Hospital, Shandong University

Department of Thoracic Surgery, The Second Hospital of Shandong University

Department of Radiology，The First Affiliated Hospital of Southern University of Science and Technology

Shantou University Medical College

⁰